直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Offices
  • Careers
Finnegan
Christopher W. Weber, Ph.D.
Associate
More
vCard
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
+1 202 408 4432
christopher.weber@finnegan.com christopher.weber@finnegan.com

Christopher W. Weber, Ph.D.

Associate

  • +1 202 408 4432 +1 202 408 4432
  • christopher.weber@finnegan.com christopher.weber@finnegan.com
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
  • vCard

Chris Weber, Ph.D., focuses on patent litigation in district and appellate courts and post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) for matters involving biotechnology and pharmaceuticals. He has experience representing pharmaceutical patent holders in Abbreviated New Drug Application (ANDA) and 505(b)(2) application litigations arising under the Hatch-Waxman Act.

Chris is involved in all aspects of patent litigation, including pre-litigation analysis; fact and expert discovery; claim construction; motions practice; trial; and handling day-to-day litigation activities. Through his opinion practice, he counsels clients on patent validity and potential product infringement. Chris's technical experience includes antibodies, gene editing technologies, transgenic animals, enzymology, chemical library screening, flow cytometry, and small molecule drugs.

Prior to law school, Chris performed research in the discovery and pre-clinical departments at a major pharmaceutical company. He received his doctorate in cell and molecular biology from the University of Pennsylvania Perelman School of Medicine, where he studied the role of deeply conserved non-coding genomic regions in the development of the vertebrate skeleton.

Chris dedicates time to pro bono representation. His efforts include drafting a successful motion to oppose summary judgment, resulting in a favorable settlement for a § 1983 prisoner claimant.

Et Cetera

  • Articles editor, Washington University Law Review, 2015-2016.

Experience

Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.

Defending Novartis against Genzyme’s patent infringement allegations related to recombinant adeno-associated virus vector technology used in Novartis’ breakthrough gene therapy Zolgensma®.

1:21-cv-01736, D. Del., Judge Andrews

American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.

Represented American Regent in litigation in the District of New Jersey against Pharmacosmos and their branded drug, Monoferric®, related to American Regent patents covering the use of iron carbohydrate complexes for the treatment of iron deficiency diseases. The case resulted in a favorable settlement for our client. This representation follows successful representation of American Regent in related post-grant review proceeding.

3:20-cv-01350, D.N.J., Judges Goodman, Martinotti, Quraishi
PGR2020-00009, PTAB, Judges Tornquist, Franklin, Wisz

Admissions and Education

Admissions

  • Illinois
  • Pennsylvania
  • U.S. Patent and Trademark Office

Admitted in Illinois and Pennsylvania only; practicing under the supervision of the partners of the Washington, DC office of Finnegan.

Education

Washington University School of Law
J.D., 2016
University of Pennsylvania Perelman School of Medicine
Ph.D., Cell and Molecular Biology, 2013
Pennsylvania State University
B.S., Biology, 2006

Christopher's Practices

Patent Litigation
Branded Hatch-Waxman (ANDA)
Patent Trial
Pre-Trial Strategy
Patent Portfolio Management, Monetization, and Transactions
Opinions and Counseling
Post-Grant Proceedings
Appeals of PTAB Trial Decisions

Christopher's Industries

Life Sciences
Biologics
Biotechnology
Pharmaceutical

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

If you have European patents, you need to know about the Unified Patent Court (UPC).

Finnegan
Click Here
  • Privacy
  • Disclaimer
  • EEO Statement

© 2022 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP